TrkA Co-Receptors: The Janus Face of TrkA?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Larotrectinib and Entrectinib are FDA-approved pan-Trk tyrosine kinase inhibitors (TKIs) for NTRK fusion cancers.
• Recent reports indicate a lack of efficacy and observed resistance to these TKIs in clinical settings.
• TrkA overexpression can lead to ligand-independent activation, bypassing TKI inhibition.

Purpose of the Study:

• To review the current therapeutic strategies involving TrkA inhibitors.
• To explore potential mechanisms underlying therapeutic failures of these inhibitors.
• To highlight the specific role of TrkA in treatment resistance.

Main Methods:

• Literature review of clinical and experimental studies on TrkA inhibitors.
• Analysis of resistance mechanisms in NTRK fusion-driven cancers.
• Examination of TrkA overexpression and its impact on TKI efficacy.

Main Results:

• Approved NTRK fusion inhibitors demonstrate variable efficacy and resistance.
• Mechanisms beyond genetic mutations, such as TrkA overexpression, contribute to treatment failure.
• Ligand-independent TrkA activation poses a challenge to current TKI therapies.

Conclusions:

• Genetic alterations alone do not fully explain therapeutic failures in NTRK fusion cancers.
• Understanding TrkA's role and alternative activation pathways is crucial for improving TKI efficacy.
• Further research into novel therapeutic strategies is warranted to overcome resistance to TrkA inhibitors.